NanoFuse Biologics adds orthobiologics executive: 3 insights

NanoFUSE Biologics appointed Archie Yamada as vice president of product business development.

Advertisement

Here are three things to know:

1. Mr. Yamada has more than 19 years of experience in the medical device industry, specifically in orthobiologics, orthopedic trauma and joints as well as neurosurgical and craniomaxillofacial implants.

2. NanoFUSE Biologics is a KICVentures-acquired portfolio company distributed by SpineFrontier.

3. The proprietary NanoFUSE Bioactive Matrix is the only FDA-cleared demineralized bone matrix and synthetic bioactive glass technology combination. The NanoFUSE DBM putty has been used in upwards of 1,000 cases by more than 200 orthopedic surgeons in various applications.

More articles on biologics:

Connect Healthcare Collaboration selects Regenexx as solution to lower employers’ orthopedic surgery costs

Zimmer Biomet to terminate exclusive distribution agreement with BoneSupport: 5 things to know

Medtronic’s Kyphon HV-R Bone Cement receives 2nd indication: 4 key points

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in Biologics

Advertisement

Comments are closed.